AMA-Published Study Notes Surge in Psilocybin Use but Blames Federal Law for Research Barriers

It looks like mushrooms are having a major moment across the U.S., with a new American Medical Association review showing that psilocybin use is skyrocketing. Much like the early days of the cannabis movement, public enthusiasm and local decriminalization are moving way faster than federal policy. The study highlights that while more adults are exploring the therapeutic potential of "magic mushrooms," the government's strict Schedule I classification is acting as a massive roadblock for researchers trying to understand real-world effects and safety.

This surge has led to some growing pains, including inconsistent potency in unregulated products and a spike in poison control calls. Experts are now calling for a shift from clinical trials using synthetic versions to studying the actual mushrooms people are using every day. For the tokers and psychonauts in our community, this is a vital step toward safety and transparency. Just like with weed, we need real-world data and honest education to replace outdated federal barriers, ensuring that accessibility doesn't come at the expense of well-being.